Wall Street analysts revise ratings and price targets for Bright Minds, Marvell and Oracle
MRVL•Analysts cut Marvell Technology ratings and price targets, while Stephens raised Oracle to overweight from equal weight and lifted its target to $213 from $185. Bright Minds Biosciences received three target cuts, including BTIG’s reduction to $37 from $147.
1. Analyst actions
Wall Street analysts revised ratings and price targets on U.S.-listed companies on Tuesday. Marvell Technology received several cuts: BofA Global Research downgraded it to neutral from buy and lowered its target to $225 from $400, while TD Cowen cut it to hold from buy and lowered its target to $175 from $350. Melius Research cut its target to $250 from $300, and RBC cut its target to $250 from $425.
2. Other notable changes
Stephens raised Oracle to overweight from equal weight and lifted its target price to $213 from $185. Bright Minds Biosciences received target cuts from Baird, BTIG and Piper Sandler; BTIG cut its target to $37 from $147, while Piper Sandler lowered its target to $115 from $220.
